30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now
United States Biotechnology & Medical Research

Heron Therapeutics Inc (HRTX)

Track

The most recent insider trading activity occurred on August 8, 2025, with significant buy transactions totaling over $6.2 million from Rubric Capital Management LP and Adam Morgan. Prior to this, in November 2023, several executives, including the CEO and CFO, made smaller buy transactions. The last reported planned sale was in May 2022.
Stock chart
Ticker: HRTX Exchange: NAS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
Rubric Capital Management LP
1 purchase — total 3,580,838 USD
Buy 8 Aug 2025
Value US$1,359,174.48 | Price 27.99 | Shares 40,479
Buy 8 Aug 2025
Value US$648,363.13 | Price 80.45 | Shares 11,530
Buy 17 Nov 2023
Value US$27,250.00 | Price 1.09 | Shares 25,000
Buy 16 Nov 2023
Value US$46,995.00 | Price 0.94 | Shares 50,000
Buy 16 Nov 2023
Value US$137,970.00 | Price 0.92 | Shares 150,000
Buy 16 Nov 2023
Value US$75,599.00 | Price 0.89 | Shares 85,000
Buy 21 Jul 2023
Value US$3,406,839.28 | Price 1.37 | Shares 2,486,744
Planned sale 3 May 2022
Value US$7,153.63 | Price 4.76 | Shares 1,504
Planned sale 21 Dec 2021
Value US$2,431.92 | Price 9.73 | Shares 250
Planned sale 21 Dec 2021
Value US$2,920.35 | Price 9.73 | Shares 300
Planned sale 21 Jun 2021
Value US$4,559.19 | Price 15.20 | Shares 300
Planned sale 21 Jun 2021
Value US$3,800.60 | Price 15.20 | Shares 250
Planned sale 15 Apr 2021
Value US$5,253.78 | Price 17.51 | Shares 300
Planned sale 6 Apr 2021
Value US$4,305.20 | Price 17.22 | Shares 250
Planned sale 14 Jan 2021
Value US$14,960.18 | Price 18.09 | Shares 827
Planned sale 8 Jan 2021
Value US$70,219.43 | Price 19.66 | Shares 3,571
Planned sale 22 Dec 2020
Value US$200,000.00 | Price 20.00 | Shares 10,000
Planned sale 1 May 2020
Value US$16,175.75 | Price 13.97 | Shares 1,158
Planned sale 29 Nov 2019
Value US$624,000.00 | Price 26.00 | Shares 24,000
Buy 4 Oct 2019
Value US$4,999,995.00 | Price 17.50 | Shares 285,714
Buy 3 Oct 2019
Value US$79,992.50 | Price 17.50 | Shares 4,571
Buy 3 Oct 2019
Value US$90,002.50 | Price 17.50 | Shares 5,143
Buy 22 May 2019
Value US$52,650.00 | Price 17.55 | Shares 3,000
Buy 15 May 2019
Value US$25,261.74 | Price 18.04 | Shares 1,400
Planned sale 1 May 2019
Value US$20,918.07 | Price 18.86 | Shares 1,109
Planned sale 2 Nov 2018
Value US$15,124.95 | Price 30.62 | Shares 494
Planned sale 1 Oct 2018
Value US$192,433.20 | Price 32.07 | Shares 6,000
Sale 12 Sep 2018
Value US$96,346,250.00 | Price 35.75 | Shares 2,695,000
Planned sale 2 Jul 2018
Value US$131,764.96 | Price 38.75 | Shares 3,400
Planned sale 2 Jul 2018
Value US$3,512,918.18 | Price 38.13 | Shares 92,131
Planned sale 2 Jul 2018
Value US$3,885.00 | Price 38.85 | Shares 100
Planned sale 2 Jul 2018
Value US$221,293.66 | Price 37.51 | Shares 5,900
Planned sale 2 Jul 2018
Value US$41,123.02 | Price 38.80 | Shares 1,060
Planned sale 2 Jul 2018
Value US$1,104,107.30 | Price 38.15 | Shares 28,940
Planned sale 29 Jun 2018
Value US$87,415.47 | Price 41.39 | Shares 2,112
Planned sale 29 Jun 2018
Value US$2,076,597.30 | Price 40.17 | Shares 51,696
Planned sale 29 Jun 2018
Value US$2,961,121.86 | Price 39.14 | Shares 75,661
Planned sale 21 Jun 2018
Value US$1,952,500.00 | Price 39.05 | Shares 50,000
Buy 29 Mar 2018
Value US$5,000,008.00 | Price 26.00 | Shares 192,308
Planned sale 19 Mar 2018
Value US$540,000.00 | Price 30.00 | Shares 18,000
Planned sale 19 Mar 2018
Value US$2,975,000.00 | Price 29.75 | Shares 100,000
Planned sale 14 Mar 2018
Value US$2,475,000.00 | Price 24.75 | Shares 100,000
Planned sale 10 Jan 2018
Value US$151,680.00 | Price 20.00 | Shares 7,584
Planned sale 24 Apr 2017
Value US$330,262.56 | Price 15.33 | Shares 21,542
Buy 19 Jan 2017
Value US$122,000.00 | Price 12.20 | Shares 10,000
Buy 19 Jan 2017
Value US$29,999,995.20 | Price 12.20 | Shares 2,459,016
Planned sale 10 Aug 2016
Value US$296,278.16 | Price 23.89 | Shares 12,400
Planned sale 10 Aug 2016
Value US$2,033,616.48 | Price 23.21 | Shares 87,600
Planned sale 21 Apr 2016
Value US$435,432.69 | Price 22.15 | Shares 19,662
Planned sale 20 Apr 2016
Value US$88,967.46 | Price 22.19 | Shares 4,010
Planned sale 19 Apr 2016
Value US$156,437.79 | Price 25.11 | Shares 6,230
Planned sale 19 Apr 2016
Value US$789,036.86 | Price 24.49 | Shares 32,224
Planned sale 19 Apr 2016
Value US$1,805,954.56 | Price 23.47 | Shares 76,949
Planned sale 19 Apr 2016
Value US$1,370,593.17 | Price 22.50 | Shares 60,925
Buy 10 Jun 2015
Value US$2,999,997.00 | Price 24.75 | Shares 121,212
Sale 2 Jun 2015
Value US$247,590.00 | Price 23.58 | Shares 10,500
Buy 2 Jun 2015
Value US$772,293.56 | Price 23.84 | Shares 32,395
Sale 1 Jun 2015
Value US$57,328.36 | Price 21.17 | Shares 2,708
Buy 1 Jun 2015
Value US$45,934.00 | Price 19.30 | Shares 2,380
Buy 29 May 2015
Value US$2,274,057.56 | Price 19.74 | Shares 115,225
Planned sale 5 Mar 2015
Value US$308,000.00 | Price 15.40 | Shares 20,000
Planned sale 5 Mar 2015
Value US$720,000.00 | Price 14.40 | Shares 50,000
Buy 25 Jun 2014
Value US$5,999,996.50 | Price 11.75 | Shares 510,638
Buy 25 Jun 2014
Value US$117,500.00 | Price 11.75 | Shares 10,000
Buy 20 Nov 2013
Value US$400,000.00 | Price 0.40 | Shares 1,000,000
Buy 25 Jul 2012
Value US$19,999,999.95 | Price 0.53 | Shares 38,095,238
Buy 19 Oct 2009
Value US$2,149,999.28 | Price 0.88 | Shares 2,443,181
Buy 31 Dec 2008
Value US$72,625.00 | Price 0.42 | Shares 175,000
Buy 18 Dec 2008
Value US$200,672.96 | Price 0.48 | Shares 415,300
Buy 13 Nov 2008
Value US$372,015.36 | Price 0.48 | Shares 775,032
Buy 13 Nov 2008
Value US$32,709.60 | Price 0.50 | Shares 66,000
Sale 10 Nov 2008
Value US$20,524.00 | Price 0.51 | Shares 40,000
Sale 10 Nov 2008
Value US$3,530.64 | Price 0.51 | Shares 6,881
Buy 31 Oct 2008
Value US$204,066.84 | Price 0.61 | Shares 336,300
Buy 10 Oct 2008
Value US$647,019.00 | Price 0.74 | Shares 870,000
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2025-08-12 2025-08-08 B Purchase
3.6
Rubric Capital Management LP
Large shareholder
40,479 +23.7%
27.99
US$1,359,174 		40,479 +23.7% 27.99 US$1,359,174
2025-08-12 2025-08-08 B Purchase
1.9
Morgan Adam
Non-Executive Director
11,530 -26.8%
80.45
US$648,363 		11,530 -26.8% 80.45 US$648,363
2023-11-21 2023-11-17 B Purchase
3.4
Forbes William P

EVP, Chief Development Officer

Officer
37,754 +43.9%
274.47
US$3,797,479 		37,754 +43.9% 274.47 US$3,797,479
2023-11-20 2023-11-16 B Purchase
3.4
Forbes William P

EVP, Chief Development Officer

Officer
50,000 +1250.0%
0.94
US$46,995 		50,000 +1250.0% 0.94 US$46,995
2023-11-17 2023-11-16 B Purchase
3.7
Collard Craig A

Chief Executive Officer

Executive Director
150,000 +411.0%
0.92
US$137,970 		150,000 +411.0% 0.92 US$137,970
2023-11-17 2023-11-16 B Purchase
3.4
Duarte Ira

EVP, Chief Financial Officer

Officer
85,000 +inf%
0.89
US$75,599 		85,000 +inf% 0.89 US$75,599
2023-07-25 2023-07-21 B Purchase
1.9
Morgan Adam
Non-Executive Director
2,486,744 +55.3%
1.37
US$3,406,839 		2,486,744 +55.3% 1.37 US$3,406,839
2022-05-04 2022-05-03 PlS Planned sale
3.0
MANHARD KIMBERLY

EVP, Drug Development

Executive Director
1,504 -12.2%
4.76
US$7,154 		1,504 -12.2% 4.76 US$7,154
2021-12-23 2021-12-21 PlS Planned sale
Johnson Craig A
Non-Executive Director
250 -8.1%
9.73
US$2,432 		250 -8.1% 9.73 US$2,432
2021-12-23 2021-12-21 PlS Planned sale
2.5
Christian Waage
Non-Executive Director
300 -8.6%
9.73
US$2,920 		300 -8.6% 9.73 US$2,920
2021-06-22 2021-06-21 PlS Planned sale
2.5
Christian Waage
Non-Executive Director
300 -7.3%
15.20
US$4,559 		300 -7.3% 15.20 US$4,559
2021-06-22 2021-06-21 PlS Planned sale
Johnson Craig A
Non-Executive Director
250 -7.0%
15.20
US$3,801 		250 -7.0% 15.20 US$3,801
2021-04-16 2021-04-15 PlS Planned sale
2.5
Christian Waage
Non-Executive Director
300 -6.8%
17.51
US$5,254 		300 -6.8% 17.51 US$5,254
2021-04-07 2021-04-06 PlS Planned sale
Johnson Craig A
Non-Executive Director
250 -6.5%
17.22
US$4,305 		250 -6.5% 17.22 US$4,305
2021-01-15 2021-01-14 PlS Planned sale
Szekeres David Leslie

EVP, Chief Operating Officer

Officer
827 -100.0%
18.09
US$14,960 		827 -100.0% 18.09 US$14,960
2021-01-08 2021-01-08 PlS Planned sale
Szekeres David Leslie

EVP, Chief Operating Officer

Officer
3,571 -100.0%
19.66
US$70,219 		3,571 -100.0% 19.66 US$70,219
2020-12-23 2020-12-22 PlS Planned sale
3.0
MANHARD KIMBERLY

EVP, Drug Development

Executive Director
10,000 -100.0%
20.00
US$200,000 		10,000 -100.0% 20.00 US$200,000
2020-05-01 2020-05-01 PlS Planned sale
3.0
MANHARD KIMBERLY

Executive VP, Drug Development

Executive Director
1,158 -100.0%
13.97
US$16,176 		1,158 -100.0% 13.97 US$16,176
2019-12-03 2019-11-29 PlS Planned sale MANHARD KIMBERLY

Executive VP, Drug Development

Executive Director
24,000 -100.0%
26.00
US$624,000 		24,000 -100.0% 26.00 US$624,000
2019-10-07 2019-10-04 B Purchase
3.3
TANG KEVIN C
285,714 +5.2%
17.50
US$4,999,995 		285,714 +5.2% 17.50 US$4,999,995
2019-10-04 2019-10-03 B Purchase
2.5
Quart Barry D

Chief Executive Officer

Executive Director
4,571 +5.1%
17.50
US$79,992 		4,571 +5.1% 17.50 US$79,992
2019-10-04 2019-10-03 B Purchase
2.8
POYHONEN JOHN

EVP, Chief Commercial Officer

Executive Director
5,143 +39.6%
17.50
US$90,002 		5,143 +39.6% 17.50 US$90,002
2019-05-23 2019-05-22 B Purchase
2.8
POYHONEN JOHN
Non-Executive Director
3,000 +30.0%
17.55
US$52,650 		3,000 +30.0% 17.55 US$52,650
2019-05-16 2019-05-15 B Purchase
2.5
Christian Waage
1,400 +inf%
18.04
US$25,262 		1,400 +inf% 18.04 US$25,262
2019-05-02 2019-05-01 PlS Planned sale
3.0
MANHARD KIMBERLY

Executive VP, Drug Development

Officer
1,109 -100.0%
18.86
US$20,918 		1,109 -100.0% 18.86 US$20,918
2018-11-02 2018-11-02 PlS Planned sale MANHARD KIMBERLY

Executive VP, Drug Development

Officer
494 -100.0%
30.62
US$15,125 		494 -100.0% 30.62 US$15,125
2018-10-02 2018-10-01 PlS Planned sale MANHARD KIMBERLY

Executive VP, Drug Development

Officer
6,000 -100.0%
32.07
US$192,433 		6,000 -100.0% 32.07 US$192,433
2018-09-12 2018-09-12 S Sale TANG KEVIN C Non-Executive Director Large shareholder
2,695,000 -31.6%
35.75
US$96,346,250 		2,695,000 -31.6% 35.75 US$96,346,250
2018-07-03 2018-07-02 PlS Planned sale Rosen Robert

President

Executive Director
3,400 -56.3%
38.75
US$131,765 		3,400 -56.3% 38.75 US$131,765
2018-07-03 2018-07-02 PlS Planned sale Rosen Robert

President

Executive Director
92,131 -93.8%
38.13
US$3,512,918 		92,131 -93.8% 38.13 US$3,512,918
2018-07-03 2018-07-02 PlS Planned sale MANHARD KIMBERLY

Executive VP, Drug Development

Officer
100 -100.0%
38.85
US$3,885 		100 -100.0% 38.85 US$3,885
2018-07-03 2018-07-02 PlS Planned sale MANHARD KIMBERLY

Executive VP, Drug Development

Officer
5,900 -98.3%
37.51
US$221,294 		5,900 -98.3% 37.51 US$221,294
2018-07-03 2018-07-02 PlS Planned sale HOFFMAN ROBERT

CFO & SVP, Finance

Officer
1,060 -45.3%
38.80
US$41,123 		1,060 -45.3% 38.80 US$41,123
2018-07-03 2018-07-02 PlS Planned sale HOFFMAN ROBERT

CFO & SVP, Finance

Officer
28,940 -92.5%
38.15
US$1,104,107 		28,940 -92.5% 38.15 US$1,104,107
2018-07-03 2018-06-29 PlS Planned sale Rosen Robert

President

Executive Director
2,112 -44.4%
41.39
US$87,415 		2,112 -44.4% 41.39 US$87,415
2018-07-03 2018-06-29 PlS Planned sale Rosen Robert

President

Executive Director
51,696 -91.6%
40.17
US$2,076,597 		51,696 -91.6% 40.17 US$2,076,597
2018-07-03 2018-06-29 PlS Planned sale Rosen Robert

President

Executive Director
75,661 -57.3%
39.14
US$2,961,122 		75,661 -57.3% 39.14 US$2,961,122
2018-06-22 2018-06-21 PlS Planned sale Quart Barry D

Chief Executive Officer

Executive Director
50,000 -41.8%
39.05
US$1,952,500 		50,000 -41.8% 39.05 US$1,952,500
2018-04-02 2018-03-29 B Purchase TANG KEVIN C Large shareholder
192,308 +2.3%
26.00
US$5,000,008 		192,308 +2.3% 26.00 US$5,000,008
2018-03-19 2018-03-19 PlS Planned sale MANHARD KIMBERLY

Executive VP, Drug Development
18,000 -100.0%
30.00
US$540,000 		18,000 -100.0% 30.00 US$540,000
2018-03-19 2018-03-19 PlS Planned sale Quart Barry D

Chief Executive Officer

Executive Director
100,000 -59.5%
29.75
US$2,975,000 		100,000 -59.5% 29.75 US$2,975,000
2018-03-16 2018-03-14 PlS Planned sale Quart Barry D

Chief Executive Officer

Executive Director
100,000 -59.5%
24.75
US$2,475,000 		100,000 -59.5% 24.75 US$2,475,000
2018-01-12 2018-01-10 PlS Planned sale MANHARD KIMBERLY

Executive VP, Drug Development

Officer
7,584 -100.0%
20.00
US$151,680 		7,584 -100.0% 20.00 US$151,680
2017-04-24 2017-04-24 PlS Planned sale MANHARD KIMBERLY

Executive VP, Drug Development
21,542 -100.0%
15.33
US$330,263 		21,542 -100.0% 15.33 US$330,263
2017-01-23 2017-01-19 B Purchase POYHONEN JOHN
10,000 +inf%
12.20
US$122,000 		10,000 +inf% 12.20 US$122,000
2017-01-23 2017-01-19 B Purchase TANG KEVIN C Non-Executive Director Large shareholder
2,459,016 +41.9%
12.20
US$29,999,995 		2,459,016 +41.9% 12.20 US$29,999,995
2016-08-12 2016-08-10 PlS Planned sale Rosen Robert

President & CCO

Executive Director
12,400 -82.4%
23.89
US$296,278 		12,400 -82.4% 23.89 US$296,278
2016-08-12 2016-08-10 PlS Planned sale Rosen Robert

President & CCO

Executive Director
87,600 -85.3%
23.21
US$2,033,616 		87,600 -85.3% 23.21 US$2,033,616
2016-04-21 2016-04-21 PlS Planned sale Rosen Robert

President

Executive Director
19,662 -88.2%
22.15
US$435,433 		19,662 -88.2% 22.15 US$435,433
2016-04-21 2016-04-20 PlS Planned sale Rosen Robert

President

Executive Director
4,010 -60.3%
22.19
US$88,967 		4,010 -60.3% 22.19 US$88,967
2016-04-21 2016-04-19 PlS Planned sale Rosen Robert

President

Executive Director
6,230 -70.2%
25.11
US$156,438 		6,230 -70.2% 25.11 US$156,438
2016-04-21 2016-04-19 PlS Planned sale Rosen Robert

President

Executive Director
32,224 -78.4%
24.49
US$789,037 		32,224 -78.4% 24.49 US$789,037
2016-04-21 2016-04-19 PlS Planned sale Rosen Robert

President

Executive Director
76,949 -65.2%
23.47
US$1,805,955 		76,949 -65.2% 23.47 US$1,805,955
2016-04-21 2016-04-19 PlS Planned sale Rosen Robert

President

Executive Director
60,925 -34.0%
22.50
US$1,370,593 		60,925 -34.0% 22.50 US$1,370,593
2015-06-12 2015-06-10 B Purchase TANG KEVIN C Non-Executive Director Large shareholder
121,212 +2.6%
24.75
US$2,999,997 		121,212 +2.6% 24.75 US$2,999,997
2015-06-03 2015-06-02 S Sale MANHARD KIMBERLY Non-Executive Director
10,500 -100.0%
23.58
US$247,590 		10,500 -100.0% 23.58 US$247,590
2015-06-02 2015-06-02 B Purchase TANG KEVIN C Non-Executive Director Large shareholder
32,395 +0.7%
23.84
US$772,294 		32,395 +0.7% 23.84 US$772,294
2015-06-03 2015-06-01 S Sale MANHARD KIMBERLY Non-Executive Director
2,708 -100.0%
21.17
US$57,328 		2,708 -100.0% 21.17 US$57,328
2015-06-02 2015-06-01 B Purchase TANG KEVIN C Non-Executive Director Large shareholder
2,380 +0.1%
19.30
US$45,934 		2,380 +0.1% 19.30 US$45,934
2015-06-02 2015-05-29 B Purchase TANG KEVIN C Non-Executive Director Large shareholder
115,225 +2.5%
19.74
US$2,274,058 		115,225 +2.5% 19.74 US$2,274,058
2015-03-09 2015-03-05 PlS Planned sale Marshall Paul

SVP, Technical Operations

Officer
20,000 -100.0%
15.40
US$308,000 		20,000 -100.0% 15.40 US$308,000
2015-03-09 2015-03-05 PlS Planned sale Marshall Paul

SVP, Technical Operations

Officer
50,000 -71.4%
14.40
US$720,000 		50,000 -71.4% 14.40 US$720,000
2014-06-27 2014-06-25 B Purchase TANG KEVIN C Non-Executive Director Large shareholder
510,638 +12.5%
11.75
US$5,999,996 		510,638 +12.5% 11.75 US$5,999,996
2014-06-26 2014-06-25 B Purchase Quart Barry D

Chief Executive Officer

Executive Director
10,000 +19.3%
11.75
US$117,500 		10,000 +19.3% 11.75 US$117,500
2013-11-21 2013-11-20 B Purchase Quart Barry D

Chief Executive Officer

Executive Director
1,000,000 +2695.4%
0.40
US$400,000 		1,000,000 +2695.4% 0.40 US$400,000
2012-09-12 2012-07-25 B Purchase SPCH, LLLP Large shareholder
38,095,238 +inf%
0.53
US$20,000,000 		38,095,238 +inf% 0.53 US$20,000,000
2009-10-21 2009-10-19 B Purchase TANG KEVIN C Non-Executive Director Large shareholder
2,443,181 +30.6%
0.88
US$2,149,999 		2,443,181 +30.6% 0.88 US$2,149,999
2009-01-05 2008-12-31 B Purchase TANG KEVIN C Large shareholder
175,000 +2.2%
0.42
US$72,625 		175,000 +2.2% 0.42 US$72,625
2008-12-22 2008-12-18 B Purchase TANG KEVIN C Large shareholder
415,300 +5.6%
0.48
US$200,673 		415,300 +5.6% 0.48 US$200,673
2008-11-17 2008-11-13 B Purchase TANG KEVIN C Large shareholder
775,032 +11.7%
0.48
US$372,015 		775,032 +11.7% 0.48 US$372,015
2008-11-17 2008-11-13 B Purchase TANG KEVIN C Large shareholder
66,000 +1.0%
0.50
US$32,710 		66,000 +1.0% 0.50 US$32,710
2008-11-12 2008-11-10 S Sale ROSENBLATT TOBY Non-Executive Director
40,000 -100.0%
0.51
US$20,524 		40,000 -100.0% 0.51 US$20,524
2008-11-12 2008-11-10 S Sale ROSENBLATT TOBY Non-Executive Director
6,881 -18.5%
0.51
US$3,531 		6,881 -18.5% 0.51 US$3,531
2008-11-04 2008-10-31 B Purchase TANG KEVIN C Large shareholder
336,300 +5.4%
0.61
US$204,067 		336,300 +5.4% 0.61 US$204,067
2008-10-14 2008-10-10 B Purchase TANG KEVIN C Large shareholder
870,000 +16.2%
0.74
US$647,019 		870,000 +16.2% 0.74 US$647,019
Explore more

More insider trading research around Heron Therapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America